Pay in 4 interest-free payments of $13.75 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657
inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4
Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells
Chemical Name: N-(4-((5-(3-(furan-2-ylmethyl)-4-oxo-1
is also a potent scavenger of NADPH-oxidase-derived superoxide
GSK-2606414 - CAS# 1337531-36-8 0435 Single-dose pharmacokinetics and pharmacodynamics ofGSK 2606414, CAS No. 1337531 36 8, is an orally available, potent, and selective PERK inhibitor. GSK 2606414 inhibits PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR) like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival
US$ 1938.00
US$ 1458.00